Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma

Area of Science:

• Immunology
• Oncology
• Bone Biology

Background:

• The immune system, particularly inflammatory cytokines like interleukin-6 (IL-6), is critical for maintaining skeletal health.
• Dysregulation of IL-6 disrupts skeletal homeostasis, leading to bone diseases such as osteoporosis, rheumatoid arthritis, and bone metastases.
• IL-6 plays a significant role in the bone marrow microenvironment (BMM), influencing cancer cell growth, metastasis, and drug resistance.

Purpose of the Study:

• To review the multifaceted roles of IL-6 in the progression of multiple myeloma (MM).
• To discuss IL-6's involvement in MM-related bone loss, cancer cell homing to the BMM, disease advancement, and the development of drug resistance.
• To explore current and potential therapeutic strategies targeting IL-6 and its downstream signaling pathways in MM.

Main Methods:

• This is a review article, synthesizing existing research on IL-6's role in multiple myeloma.
• Literature search and analysis focusing on the molecular mechanisms of IL-6 in bone metabolism and cancer progression.
• Discussion of therapeutic interventions targeting IL-6 and associated signaling molecules.

Main Results:

• IL-6 overexpression is strongly associated with multiple myeloma and significant bone loss.
• IL-6 promotes osteoclastogenesis, leading to excessive bone resorption and osteolysis within the BMM.
• IL-6 contributes to MM progression by facilitating cancer cell homing, supporting tumor growth, and fostering drug-resistant clones.

Conclusions:

• IL-6 is a key mediator of bone destruction and disease progression in multiple myeloma.
• Targeting IL-6 and its signaling network presents a viable therapeutic approach, particularly for overcoming drug resistance and improving patient outcomes.
• Microenvironment-targeted therapies focusing on IL-6 offer a promising strategy for managing MM and associated skeletal complications.